NemaMetrix, a company developing nematode-based drug development and screening technologies, announced the launch of its first series of RediStain™ fluorescent kits for improved visualization of C. elegans’ structure and function in phenotyping studies. These kits expand the toolkit of C. elegans research to include the ability to perform structural and functional assays that are standard in cell biology.
News & Events
Visit the Knudra/NemaMetrix joint booth at the 21st International C. elegans Meeting to learn latest trends and applications in C. elegans research.
NemaMetrix Inc. was selected as the only company representing the state of Oregon by the Science Coalition in its latest Sparking Economic Growth reports released Apr 25, 2017.
Nemametrix Inc., a life sciences startup that created the innovative ScreenChip System for drug screening, mutant phenotyping, and toxicological assessment, has entered into a marketing partnership with Knudra Transgenics, a genome engineering company specializing in custom built transgenic model organisms for research and drug discovery.
Our Co-founder, Dr. Weeks, gave an impassioned scientific talk in Gabon, discussing her work at the University of Oregon that led her to start NemaMetrix and receive a Bill & Melinda Gates Foundation grant for global health research.
The NemaMetrix ScreenChip platform technology was recognized by the White House as one of the breakthrough life science research technologies. CEO Matt Beaudet spoke with Dr. Robbie Barbero of the US White House Office of Science and Technology Policy, who created a post on the White House website about the promise of new research technologies.
NemaMetrix announces being awarded $249,000 in GAP funding from Oregon Nanoscience and Microtechnologies Institute (ONAMI) to fund “proof-of-concept” work and to fuel development towards commercialization.
NemaMetrix announces being awarded $188,000 for a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Health. The funds will be used to support fundamental proof of concept research, with an eye towards near-term commercialization, of a microfluidic screening device for health-span extending drugs.